On December 4, 2025 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, reported that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10-12, 2025, in London, United Kingdom.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
• Conference: ESMO (Free ESMO Whitepaper) Immuno-Oncology (ESMO-IO) 2025 Annual Congress
• Title: CAPTN-3 unique design demonstrated by 2 novel platform compounds
• Presenter: Dr. Hadas Reuveni
• Presentation Number: FPN# 287P
• Session Title: Poster Presentation
• Date/Time: Wednesday, December 10, 2025, 17:15
• Location: London, UK
"Our CAPTN-3 platform can produce novel tri-specific antibodies that engage T cells, NK cells and bind to tumor associated antigens. The powerful synergy we have seen in preclinical studies strengthens our conviction in not only the platform, but also in this novel structure to overcome tumor evasion and drug resistance. We look forward to showcasing new data from our lead CAPTN-3 program, IM1240, in multiple PD-1 resistant models, and new data demonstrating the platform versatility with multiple tri-specific antibodies" said Gil Efron, Chief Executive Officer of Purple Biotech, Ltd.
The poster will be accessible under the Publications section of the Purple Biotech website following the congress.
(Press release, Purple Biotech, DEC 4, 2025, View Source;id=374459&p=2412439&I=1206939-c7Z3G6f3m8 [SID1234661130])